Sharechat Logo

Fencemaker's testing time

Shoeshine

Friday 14th November 2003

Text too small?
A lot of ingenuity was expended this week working out theories on who's behind the appearance of Tru-Test-bashing coverage in the media and why.

The issues are old ones. First, the company didn't live up to the 2001 information memorandum ebitda (earnings before interest, tax, depreciation and amortisation) forecast of $18.3 million for the August 2002 year.

That's disappointing for everyone but in the context of a rocketing exchange rate, low beef prices for Tru-Test's customers and the Australian drought, it's scarcely surprising.

The Neuronz purchase has also aggravated some shareholders but, like the company's financial performance, that was known before last year's annual meeting, at which, apparently, no questions were asked.

The theory getting most traction is that someone is trying to unsettle shareholders and turn up the gas on Tru-Test's board and management to smooth the path of a takeover.

The natural candidate for the bidder is Skellmax Industries, whose largest shareholder, Axa Asia Pacific, has 5.67%.

It's a small country. Axa is also one of Tru-Test's shareholders.

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 2nd Morning Report
SkyCity Announces Official Opening Date for NZICC
December 1st Morning Report
RAK - 1H26: Strong first half growth and strategic momentum
Green Cross Health Interim Results to 30 September 2025
Devon Funds Morning Note - 28 November 2025
November 28th Morning Report
Pacific Edge Appoints Chief Commercial Officer
Ryman Healthcare reports 1H26 results
Tower reports record FY25 result, increased dividends